Regenxbio Inc (RGNX) - Net Assets
Based on the latest financial reports, Regenxbio Inc (RGNX) has net assets worth $21.08 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($341.89 Million) and total liabilities ($320.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Regenxbio Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $21.08 Million |
| % of Total Assets | 6.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | -86.56% |
| 10-Year Change | -36.48% |
| Growth Volatility | 70.07 |
Regenxbio Inc - Net Assets Trend (2013–2025)
This chart illustrates how Regenxbio Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Regenxbio Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Regenxbio Inc (2013–2025)
The table below shows the annual net assets of Regenxbio Inc from 2013 to 2025. For live valuation and market cap data, see market cap of Regenxbio Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $102.73 Million | -60.43% |
| 2024-12-31 | $259.65 Million | -16.71% |
| 2023-12-31 | $311.74 Million | -39.61% |
| 2022-12-31 | $516.20 Million | -32.46% |
| 2021-12-31 | $764.30 Million | +102.33% |
| 2020-12-31 | $377.75 Million | -16.09% |
| 2019-12-31 | $450.20 Million | -11.53% |
| 2018-12-31 | $508.85 Million | +178.01% |
| 2017-12-31 | $183.03 Million | +13.16% |
| 2016-12-31 | $161.74 Million | -25.40% |
| 2015-12-31 | $216.81 Million | +3904.98% |
| 2014-12-31 | $-5.70 Million | -165.89% |
| 2013-12-31 | $-2.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Regenxbio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 110122100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $-687.00K | -0.67% |
| Other Components | $1.23 Billion | 1196.74% |
| Total Equity | $102.73 Million | 100.00% |
Regenxbio Inc Competitors by Market Cap
The table below lists competitors of Regenxbio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BLD Plantation Bhd
KLSE:5069
|
$316.91 Million |
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
$316.98 Million |
|
Sidus Space Inc
NASDAQ:SIDU
|
$317.03 Million |
|
RiverNorth Flexible Municipal Income Fund II Inc
NYSE:RFMZ
|
$317.06 Million |
|
Suzhou Shijing Environmental Technology Co.Ltd.
SHE:301030
|
$316.88 Million |
|
Patel Engineering Limited
NSE:PATELENG
|
$316.88 Million |
|
Ercros
MC:ECR
|
$316.83 Million |
|
Southern Score Builders Berhad
KLSE:0045
|
$316.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Regenxbio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 259,651,000 to 102,733,000, a change of -156,918,000 (-60.4%).
- Net loss of 193,878,000 reduced equity.
- Share repurchases of 1,048,000 reduced equity.
- New share issuances of 1,048,000 increased equity.
- Other comprehensive income increased equity by 54,000.
- Other factors increased equity by 36,906,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-193.88 Million | -188.72% |
| Share Repurchases | $1.05 Million | -1.02% |
| Share Issuances | $1.05 Million | +1.02% |
| Other Comprehensive Income | $54.00K | +0.05% |
| Other Changes | $36.91 Million | +35.92% |
| Total Change | $- | -60.43% |
Book Value vs Market Value Analysis
This analysis compares Regenxbio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.81 | $7.90 | x |
| 2014-12-31 | $-0.43 | $7.90 | x |
| 2015-12-31 | $23.64 | $7.90 | x |
| 2016-12-31 | $6.12 | $7.90 | x |
| 2017-12-31 | $6.13 | $7.90 | x |
| 2018-12-31 | $13.88 | $7.90 | x |
| 2019-12-31 | $12.27 | $7.90 | x |
| 2020-12-31 | $10.13 | $7.90 | x |
| 2021-12-31 | $17.40 | $7.90 | x |
| 2022-12-31 | $11.96 | $7.90 | x |
| 2023-12-31 | $7.13 | $7.90 | x |
| 2024-12-31 | $5.24 | $7.90 | x |
| 2025-12-31 | $1.99 | $7.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Regenxbio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -188.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -113.75%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 4.41x
- Recent ROE (-188.72%) is below the historical average (-39.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -88.50% | 2.43x | 0.00x | $-5.17 Million |
| 2014 | 0.00% | -65.41% | 1.75x | 0.00x | $-3.43 Million |
| 2015 | -10.52% | -300.62% | 0.03x | 1.02x | $-44.49 Million |
| 2016 | -38.93% | -1372.13% | 0.03x | 1.07x | $-79.14 Million |
| 2017 | -39.98% | -704.02% | 0.05x | 1.09x | $-91.47 Million |
| 2018 | 19.64% | 45.74% | 0.40x | 1.07x | $49.05 Million |
| 2019 | -21.04% | -268.88% | 0.07x | 1.11x | $-139.75 Million |
| 2020 | -29.45% | -71.98% | 0.22x | 1.87x | $-149.03 Million |
| 2021 | 16.73% | 27.18% | 0.42x | 1.46x | $51.41 Million |
| 2022 | -54.31% | -248.68% | 0.14x | 1.61x | $-331.94 Million |
| 2023 | -84.52% | -291.99% | 0.16x | 1.84x | $-294.67 Million |
| 2024 | -87.46% | -272.54% | 0.18x | 1.79x | $-253.07 Million |
| 2025 | -188.72% | -113.75% | 0.38x | 4.41x | $-204.15 Million |
Industry Comparison
This section compares Regenxbio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Regenxbio Inc (RGNX) | $21.08 Million | 0.00% | 15.22x | $316.91 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more